<DOC>
	<DOCNO>NCT01710644</DOCNO>
	<brief_summary>The purpose Randomized , Double-blind , Multicenter , Two-period Crossover Study Assess Efficacy Tolerability Burlulipase ( NM-BL ) Patients Exocrine Pancreatic Insufficiency due Cystic Fibrosis</brief_summary>
	<brief_title>Efficacy Tolerability NM-BL Patients With Exocrine Pancreatic Insufficiency Due Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>Male female patient age ≥12 year date inform consent Confirmed diagnosis CF screening Confirmed EPI historical ( within past 12 month ) CFA &lt; 70 % without use PERTs current fecal elastase &lt; 50 µg/g stool screen Currently receive PERT commercially available pancreatic enzyme Currently stable treatment proton pump inhibitor H2 receptor antagonist Clinically stable condition without evidence acute respiratory disease acute condition History fibrosing colonopathy History significant bowel resection , opinion investigator , solid organ transplant History refractory pancreatic enzyme replacement Current diagnosis history distal intestinal obstruction syndrome Current diagnosis small intestinal bacterial overgrowth , ileus acute abdomen A body mass index percentile &lt; 10 %</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>